Overview
Cholestasis is the impairment or cessation of bile flow from the liver to the duodenum. It can be intrahepatic (hepatocyte or bile ductule dysfunction) or extrahepatic (mechanical obstruction). Beyond its direct hepatic consequences, cholestasis profoundly disrupts the gut microbiome by removing bile acids — a major ecological regulator — from the intestinal environment.
Microbiome Associations
Bile acids are potent antimicrobial agents that shape gut community composition, particularly suppressing Gram-positive bacteria. When bile flow stops, the gut microbiome undergoes dramatic restructuring: small intestinal bacterial overgrowth (SIBO) develops, bile-tolerant taxa decline, and bile-sensitive organisms expand. The loss of bile-mediated FXR signaling in the ileum disrupts the enterohepatic feedback loop that normally regulates bile acid metabolism.
Metal Associations
Cholestatic liver disease leads to copper and manganese accumulation in hepatic tissue, as biliary excretion is the primary elimination route for both metals. Retained copper drives oxidative damage through Fenton-like chemistry, while manganese retention may contribute to the hepatic encephalopathy seen in advanced cholestatic disease. Iron handling is also disrupted through hepcidin dysregulation.
Associated Conditions
Cholestasis is a feature of primary-biliary-cholangitis, primary-sclerosing-cholangitis, and drug-induced liver injury. It also occurs in non alcoholic fatty liver disease progression. The shared metal accumulation pattern — particularly copper — across cholestatic conditions suggests a common metallotoxic pathway compounding the primary biliary insult.
Open Questions
Whether microbiome restoration (via bile acid supplementation or targeted probiotics) can mitigate hepatic metal accumulation in chronic cholestasis is an emerging research question.
Cross-References
- bile acid metabolism — disrupted enterohepatic circulation
- copper — hepatic accumulation in cholestasis
- manganese — biliary excretion impairment
- gut-liver-axis — bidirectional liver-microbiome signaling